Skip to content

Clinical trials

Phase 1 Carcinoma, Non-Small-Cell Lung trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Carcinoma, Non-Small-Cell Lung Phase: Phase 1 Country / region: China Clear all

179 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20071
20081
20092
20111
20122
20142
20152
201612
20175
20188
201916
202014
202113
202222
202311
202425
202530
202612

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting58
Unknown status44
Completed32
Active, not recruiting22
Not yet recruiting12
Terminated8
Withdrawn2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Betta Pharmaceuticals Co., Ltd.6
Sichuan Baili Pharmaceutical Co., Ltd.6
Jiangsu Hansoh Pharmaceutical Co., Ltd.5
Shenzhen TargetRx Co., Ltd.5
Sichuan University5
Eli Lilly and Company4
Jiangsu Simcere Pharmaceutical Co., Ltd.4
Sun Yat-sen University4
Bayer3
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Carcinoma, Non-Small-Cell Lung179
Colorectal Neoplasms28
Squamous Cell Carcinoma of Head and Neck18
Melanoma16
Breast Neoplasms13
Lung Neoplasms13
Esophageal Neoplasms11
Carcinoma, Hepatocellular9
Carcinoma, Renal Cell9
Neoplasm Metastasis9

Trials

Showing 1 to 25 of 179. Each trial links to its page on Pharma Observatory.

79 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.